Article
Fasenra shows positive PhIII topline data for nasal polyps, tightening race with GSK's Nucala
Rating:
0.0
Views:
65
Likes:
1
Library:
1
The highly contested respiratory field just got even tighter Thursday. AstraZeneca revealed topline data for a Phase III trial Thursday evaluating its Fasenra asthma therapy in a new indication — chronic rhinosinusitis with nasal polyps. The British drugmaker said the drug met both co-primary endpoints in patients who did not
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value